Rover Dx is developing a point-of-care testing device that brings lab based methodology into OB/GYN clinics with results in
15 minutes.​
Introducing Rover LightSpeed
RECEIVED 2020
National Institute of Health
RadX grant recipient
2022 PUBLICATION
Rover Dx's nanotechnology
featured in Nature science journal
New York State Biodefense
Commercialization grant
2022 PUBLICATION
RoverDx's nanotechnology
featured in Nature science journal
Rover Dx is passionate about advancing healthcare innovation
for women.
That's why the first panel we are developing is for women's health. Shortening the time between diagnosis and treatment would improve the well-being of millions of women lives annually.
OUR INITIAL PANEL WILL FOCUS ON THE FOLLOWING CONDITIONS:
Bacterial
Vaginosis
There are 21.2 million cases of bacterial vaginosis reported annually.
1
Vulvovaginal
Candidiasis
An estimated 75% of all women have at least one episode of vulvovaginal candidiasis in their lifetime.
2
Trichomoniasis
70% of patients with trichomoniasis
are asymptomatic.
3
Accurate, easy-to-use,
point-of-care testing streamlines the treatment process for OB/GYNs.